Clovis Withdraws Rubraca Ovarian Cancer Indication Due To Survival Imbalance

 
• By Joseph Haas
  
OvarianCancer_1200x675
Clovis's timeline for adding to Rubraca's ovarian cancer labeling is uncertain
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D